J. Ferlay, M. Colombet, I. Soerjomataram, C. Mathers, D. M. Parkin et al., Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods, Int J Cancer, vol.15, issue.8, pp.1941-53, 2019.

K. Ligier, A. Belot, G. Launoy, M. Velten, P. Delafosse et al.,

, Rev Stomatol Chir Maxillofac. juin, vol.112, issue.3, pp.164-71, 2011.

E. L. Franco, L. L. Dib, D. S. Pinto, V. Lombardo, and H. Contesini, Race and gender influences on the survival of patients with mouth cancer, J Clin Epidemiol. janv, vol.46, issue.1, pp.37-46, 1993.

G. F. Funk, L. H. Karnell, R. A. Robinson, W. K. Zhen, D. K. Trask et al., Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report, Head Neck. févr, vol.24, issue.2, pp.165-80, 2002.

M. Kuriakose, M. Sankaranarayanan, M. K. Nair, T. Cherian, A. W. Sugar et al., Comparison of oral squamous cell carcinoma in younger and older patients in India, Eur J Cancer, B, Oral Oncol, vol.28, issue.2, pp.113-133, 1992.

H. Platz, R. Fries, M. Hudec, M. Tjoa, A. Wagner et al., The prognostic relevance of various factors at the time of the first admission of the patient. Retrospective DOSAK study on carcinoma of the oral cavity, J Maxillofac Surg. févr, vol.11, issue.1, pp.3-12, 1983.

K. De-cássia-braga-ribeiro, L. P. Kowalski, and M. Latorre, Perioperative complications, comorbidities, and survival in oral or oropharyngeal cancer, Arch Otolaryngol Head Neck Surg. févr, vol.129, issue.2, pp.219-247, 2003.

J. A. Woolgar, J. Scott, E. D. Vaughan, J. S. Brown, C. R. West et al., Survival, metastasis and recurrence of oral cancer in relation to pathological features, Ann R Coll Surg Engl. sept, vol.77, issue.5, pp.325-356, 1995.

S. T. Ildstad, M. E. Bigelow, and J. P. Remensnyder, Squamous cell carcinoma of the tongue: a comparison of the anterior two thirds of the tongue with its base, Am J Surg, vol.146, issue.4, pp.456-61, 1983.

J. A. Woolgar, S. Rogers, C. R. West, R. D. Errington, J. S. Brown et al., Survival and patterns of recurrence in 200 oral cancer patients treated by radical surgery and neck dissection, Oral Oncol. mai, vol.35, issue.3, pp.257-65, 1999.

W. A. Maddox, Hayes Martin lecture. Vicissitudes of head and neck cancer, Am J Surg, vol.148, issue.4, pp.428-460, 1984.

A. S. Jones, Prognosis in mouth cancer: tumour factors, Eur J Cancer, B, Oral Oncol. janv, vol.30, issue.1, pp.8-15, 1994.

L. P. Kowalski and H. F. Köhler, Relevant changes in the AJCC 8th edition staging manual for oral cavity cancer and future implications, Chin Clin Oncol. 20 mars, 2019.

N. Moeckelmann, A. Ebrahimi, Y. K. Tou, R. Gupta, T. Low et al., Prognostic implications of the 8th edition American Joint Committee on Cancer (AJCC) staging system in oral cavity squamous cell carcinoma, Oral Oncol. oct, vol.85, pp.82-88, 2018.

R. H. Spiro, A. G. Huvos, G. Y. Wong, J. D. Spiro, C. A. Gnecco et al., Predictive value of tumor thickness in squamous carcinoma confined to the tongue and floor of the mouth, Am J Surg, vol.152, issue.4, pp.345-50, 1986.

A. Nathanson, K. Agren, A. Biörklund, M. G. Lind, L. Andréason et al., Evaluation of some prognostic factors in small squamous cell carcinoma of the mobile tongue: a multicenter study in Sweden. Head Neck, vol.11, pp.387-92, 1989.

S. Baredes, D. J. Leeman, T. S. Chen, and M. A. Mohit-tabatabai, Significance of tumor thickness in soft palate carcinoma, Laryngoscope. avr, vol.103, issue.4, pp.389-93, 1993.

P. Wing-yuen, A. Lam, K. Y. Lam, L. K. Ho, C. M. Wong et al., Prognostic factors of clinically stage I and II oral tongue carcinoma-A comparative study of stage, thickness, shape, growth pattern, invasive front malignancy grading, Martinez-Gimeno score, and pathologic features, Head Neck. juin, vol.24, issue.6, pp.513-533, 2002.

P. O-charoenrat, G. Pillai, S. Patel, C. Fisher, D. Archer et al., Primary tumor staging for oral cancer and a proposed modification incorporating depth of invasion: an international multicenter retrospective study, JAMA Otolaryngol Head Neck Surg. déc, vol.39, issue.4, pp.1138-1186, 2003.

S. J. Shim, J. Cha, W. S. Koom, G. E. Kim, C. G. Lee et al., Clinical outcomes for T1-2N0-1 oral tongue cancer patients underwent surgery with and without postoperative radiotherapy, Radiat Oncol. 27 mai, vol.5, p.43, 2010.

P. Scholl, R. M. Byers, J. G. Batsakis, P. Wolf, and H. Santini, Microscopic cut-through of cancer in the surgical treatment of squamous carcinoma of the tongue. Prognostic and therapeutic implications, Am J Surg, vol.152, issue.4, pp.354-60, 1986.

D. N. Sutton, J. S. Brown, S. N. Rogers, E. D. Vaughan, and J. A. Woolgar, The prognostic implications of the surgical margin in oral squamous cell carcinoma, Int J Oral Maxillofac Surg. févr, vol.32, issue.1, pp.30-34, 2003.

T. R. Loree and E. W. Strong, Significance of positive margins in oral cavity squamous carcinoma, Am J Surg. oct, vol.160, issue.4, pp.410-414, 1990.

G. B. Snow, A. A. Annyas, E. A. Van-slooten, H. Bartelink, and A. A. Hart, Prognostic factors of neck node metastasis, Clin Otolaryngol Allied Sci. juin, vol.7, issue.3, pp.185-92, 1982.

I. K. Kalnins, A. G. Leonard, K. Sako, M. S. Razack, and D. P. Shedd, Correlation between prognosis and degree of lymph node involvement in carcinoma of the oral cavity, Am J Surg, vol.134, issue.4, pp.450-454, 1977.

H. Kokemueller, P. Brachvogel, A. Eckardt, and J. E. Hausamen, Neck dissection in oral cancer--clinical review and analysis of prognostic factors, Int J Oral Maxillofac Surg. déc, vol.31, issue.6, pp.608-622, 2002.

S. Shingaki, M. Takada, K. Sasai, R. Bibi, T. Kobayashi et al., Impact of lymph node metastasis on the pattern of failure and survival in oral carcinomas, Am J Surg. mars, vol.185, issue.3, pp.278-84, 2003.

L. Tourneau, C. Velten, M. Jung, G. Bronner, G. Flesch et al., Prognostic indicators for survival in head and neck squamous cell carcinomas: analysis of a series of 621 cases, Head Neck. sept, vol.27, issue.9, pp.801-809, 2005.

J. A. Woolgar, S. N. Rogers, D. Lowe, J. S. Brown, and E. D. Vaughan, Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread, Oral Oncol. févr, vol.39, issue.2, pp.130-137, 2003.

J. N. Myers, J. S. Greenberg, V. Mo, D. Roberts, V. B. Wreesmann et al., Extracapsular spread. A significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue, Cancer. 15 déc, vol.92, issue.12, pp.1192-1199, 2001.

J. De-juan, J. García, M. López, C. Orús, E. Esteller et al., Inclusion of extracapsular spread in the pTNM classification system: a proposal for patients with head and neck carcinoma, JAMA Otolaryngol Head Neck Surg. mai, vol.139, issue.5, pp.483-491, 2013.

K. Arthur and H. W. Farr, Prognostic significance of histologic grade in epidermoid carcinoma of the mouth and pharynx, Am J Surg, vol.124, issue.4, pp.489-92, 1972.

M. Shear, D. M. Hawkins, and H. W. Farr, The prediction of lymph node metastases from oral squamous carcinoma, Cancer. avr, vol.37, issue.4, pp.1901-1908, 1976.

L. G. Close, P. M. Brown, M. F. Vuitch, J. Reisch, and S. D. Schaefer, Microvascular invasion and survival in cancer of the oral cavity and oropharynx, Arch Otolaryngol Head Neck Surg, vol.115, issue.11, pp.1304-1313, 1989.

B. Rahima, S. Shingaki, M. Nagata, and C. Saito, Prognostic significance of perineural invasion in oral and oropharyngeal carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, avr, vol.97, issue.4, pp.423-454, 2004.

J. J. Fagan, B. Collins, L. Barnes, D. 'amico, F. Myers et al., Perineural invasion in squamous cell carcinoma of the head and neck, Arch Otolaryngol Head Neck Surg. juin, vol.124, issue.6, pp.637-677, 1998.

R. J. Shaw, J. S. Brown, J. A. Woolgar, D. Lowe, S. N. Rogers et al., The influence of the pattern of mandibular invasion on recurrence and survival in oral squamous cell carcinoma. Head Neck, vol.26, pp.861-870, 2004.

R. D. Cole and W. F. Mcguirt, Prognostic significance of skin involvement from mucosal tumors of the head and neck. Arch Otolaryngol Head Neck Surg, vol.121, pp.1246-1254, 1995.

F. Penault-llorca, X. Durando, and J. Bay, Prognostic value of epidermal growth factor receptor, Bull Cancer, vol.90, pp.192-196, 2003.

R. I. Nicholson, J. M. Gee, and M. E. Harper, EGFR and cancer prognosis, Eur J Cancer. sept, vol.37, issue.4, pp.9-15, 2001.

J. A. Bonner, P. M. Harari, J. Giralt, N. Azarnia, D. M. Shin et al., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N Engl J Med. 9 févr, vol.354, issue.6, pp.567-78, 2006.

B. Burtness, M. A. Goldwasser, W. Flood, B. Mattar, and A. A. Forastiere,

, Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study, J Clin Oncol. 1 déc, vol.23, issue.34, pp.8646-54, 2005.

J. Baselga, J. M. Trigo, J. Bourhis, J. Tortochaux, H. Cortés-funes et al., Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck, J Clin Oncol. 20 août, vol.23, issue.24, pp.5568-77, 2005.

J. B. Vermorken, J. Trigo, R. Hitt, P. Koralewski, E. Diaz-rubio et al., Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinumbased therapy, J Clin Oncol. 1 juin, vol.25, issue.16, pp.2171-2178, 2007.

P. Fouret, G. Monceaux, S. Temam, L. Lacourreye, and J. L. St-guily, Psyrri A, DiMaio D. Human papillomavirus in cervical and head-and-neck cancer, Arch Otolaryngol Head Neck Surg. mai, vol.123, issue.5, pp.24-31, 1997.

K. K. Ang, J. Harris, R. Wheeler, R. Weber, D. I. Rosenthal et al., Human papillomavirus and survival of patients with oropharyngeal cancer, N Engl J Med. 1 juill, vol.363, issue.1, pp.24-35, 2010.

C. Fakhry, W. H. Westra, S. Li, A. Cmelak, J. A. Ridge et al., Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial, J Natl Cancer Inst. 20 févr, vol.100, issue.4, pp.261-270, 2008.

H. C. Hafkamp, J. J. Manni, A. Haesevoets, A. C. Voogd, M. Schepers et al., Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas, Int J Cancer. 15 juin, vol.122, issue.12, pp.2656-64, 2008.

M. J. Caminero, F. Núñez, C. Suárez, P. Ablanedo, J. R. Riera et al., p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma, Arch Otolaryngol Head Neck Surg. juill, vol.122, issue.7, pp.1580-1586, 1996.

C. De-vicente, J. , J. Gutiérrez, L. M. Zapatero, A. H. et al., Prognostic significance of p53 expression in oral squamous cell carcinoma without neck node metastases, Head Neck. janv, vol.26, issue.1, pp.22-30, 2004.

C. Couture, H. Raybaud-diogène, B. Têtu, I. Bairati, D. Murry et al., p53 and Ki-67 as markers of radioresistance in head and neck carcinoma, Cancer. 1 févr, vol.94, issue.3, pp.713-735, 2002.

S. Temam, A. Flahault, S. Périé, G. Monceaux, F. Coulet et al., p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck, J Clin Oncol. janv, vol.18, issue.2, pp.385-94, 2000.

A. Cabelguenne, H. Blons, I. De-waziers, F. Carnot, A. M. Houllier et al., p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series, J Clin Oncol. avr, vol.18, issue.7, pp.1465-73, 2000.

R. J. Michalides, N. M. Van-veelen, P. M. Kristel, A. A. Hart, B. M. Loftus et al., Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck, Arch Otolaryngol Head Neck Surg. mai, vol.123, issue.5, pp.497-502, 1997.

S. D. Meredith, P. A. Levine, J. A. Burns, M. J. Gaffey, J. C. Boyd et al., Chromosome 11q13 amplification in head and neck squamous cell carcinoma. Association with poor prognosis, Arch Otolaryngol Head Neck Surg. juill, vol.121, issue.7, pp.790-794, 1995.

W. M. Lydiatt, S. G. Patel, B. O'sullivan, M. S. Brandwein, J. A. Ridge et al., Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual, CA Cancer J Clin, vol.67, issue.2, pp.122-159, 2017.

J. Mork, A. K. Lie, E. Glattre, G. Hallmans, E. Jellum et al., Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck, N Engl J Med. 12 avr, vol.344, issue.15, pp.1125-1156, 2001.

H. Mirghani, F. Amen, F. Moreau, L. St-guily, and J. , Do high-risk human papillomaviruses cause oral cavity squamous cell carcinoma?, Oral Oncol. mars, vol.51, issue.3, pp.229-265, 2015.

L. Vecchia, C. Negri, E. , D. 'avanzo, B. Boyle et al., Dietary indicators of oral and pharyngeal cancer, Int J Epidemiol. mars, vol.20, issue.1, pp.39-44, 1991.

N. Homann, J. Tillonen, J. H. Meurman, H. Rintamäki, C. Lindqvist et al., Increased salivary acetaldehyde levels in heavy drinkers and smokers: a microbiological approach to oral cavity cancer, Carcinogenesis. avr, vol.21, issue.4, pp.663-671, 2000.

J. Pignon, A. Le-maître, E. Maillard, J. Bourhis, . Mach-nc-collaborative et al., Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients, Radiother Oncol. juill, vol.92, issue.1, pp.4-14, 2009.

J. Bernier, C. Domenge, M. Ozsahin, K. Matuszewska, J. Lefèbvre et al., Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer, N Engl J Med. 6 mai, vol.350, issue.19, pp.1945-52, 2004.

J. S. Cooper, T. F. Pajak, A. A. Forastiere, J. Jacobs, B. H. Campbell et al., Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck, N Engl J Med. 6 mai, vol.350, issue.19, pp.1937-1981, 2004.

E. Cohen, T. G. Karrison, M. Kocherginsky, J. Mueller, R. Egan et al., Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer, J Clin Oncol. 1 sept, vol.32, issue.25, pp.2735-2778, 2014.

R. Haddad, A. O'neill, G. Rabinowits, R. Tishler, F. Khuri et al., Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial, Lancet Oncol. mars, vol.14, issue.3, pp.257-64, 2013.

R. Hitt, J. J. Grau, A. López-pousa, A. Berrocal, C. García-girón et al., A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer, Ann Oncol. janv, vol.25, issue.1, pp.216-241, 2014.

M. G. Ghi, A. Paccagnella, D. Ferrari, P. Foa, D. Alterio et al., Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial, Ann Oncol. 1 sept, vol.28, issue.9, pp.2206-2218, 2017.

J. Guigay, J. Fayette, A. F. Dillies, C. Sire, J. N. Kerger et al., Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study, Ann Oncol. sept, vol.26, issue.9, pp.1941-1948, 2015.

R. L. Ferris, G. Blumenschein, F. J. Guigay, J. Colevas, A. D. Licitra et al., Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck, N Engl J Med, vol.10, pp.1856-67, 2016.

F. S. Hodi, S. J. O'day, D. F. Mcdermott, R. W. Weber, J. A. Sosman et al., Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, vol.363, issue.8, pp.711-734, 2010.

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1666, 2015.

R. J. Motzer, B. Escudier, D. F. Mcdermott, S. George, H. J. Hammers et al., Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, N Engl J Med, vol.373, pp.1803-1816, 2015.

J. E. Rosenberg, J. Hoffman-censits, T. Powles, M. S. Van-der-heijden, A. V. Balar et al.,

, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet. 7 mai, vol.387, pp.1909-1929, 2016.

J. D. Wolchok, V. Chiarion-sileni, R. Gonzalez, P. Rutkowski, J. Grob et al., Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, N Engl J Med. 05, vol.377, issue.14, pp.1345-56, 2017.

R. J. Motzer, N. M. Tannir, D. F. Mcdermott, A. Frontera, O. Melichar et al., Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma, N Engl J Med. 5 avr, vol.378, issue.14, pp.1277-90, 2018.

A. Ribas, O. Hamid, A. Daud, F. S. Hodi, J. D. Wolchok et al., Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma, JAMA. 19 avr, vol.315, issue.15, pp.1600-1609, 2016.

C. Robert, G. V. Long, B. Brady, C. Dutriaux, M. Maio et al., Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med. 22 janv, vol.372, issue.4, pp.320-350, 2015.

J. Brahmer, K. L. Reckamp, P. Baas, L. Crinò, W. Eberhardt et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med. 9 juill, vol.373, issue.2, pp.123-158, 2015.

E. Cohen, D. Soulières, L. Tourneau, C. Dinis, J. Licitra et al., Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study, Lancet, vol.12, pp.156-67, 2019.

L. F. Licitra, R. I. Haddad, C. Even, M. Tahara, M. Dvorkin et al., A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), JCO. 20 mai, vol.37, pp.6012-6012, 2019.

T. Powles, I. Durán, M. S. Van-der-heijden, Y. Loriot, N. J. Vogelzang et al., Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial, Lancet, vol.24, pp.748-57, 2018.

D. P. Carbone, M. Reck, L. Paz-ares, B. Creelan, L. Horn et al., First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer, N Engl J Med, vol.22, issue.25, pp.2415-2441, 2017.

M. Reck, D. Rodríguez-abreu, A. G. Robinson, R. Hui, T. Cs?szi et al., Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.10, issue.19, pp.1823-1856, 2016.

A. Zehir, R. Benayed, R. H. Shah, A. Syed, S. Middha et al., Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients, Nat Med. juin, vol.23, issue.6, pp.703-716, 2017.

M. S. Lawrence, P. Stojanov, P. Polak, G. V. Kryukov, K. Cibulskis et al., Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature. 11 juill, vol.499, issue.7457, pp.214-222, 2013.

Z. R. Chalmers, C. F. Connelly, D. Fabrizio, L. Gay, S. M. Ali et al., Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, Genome Med, vol.19, issue.1, p.34, 2017.

D. T. Le, J. N. Uram, H. Wang, B. R. Bartlett, H. Kemberling et al., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N Engl J Med. 25 juin, vol.372, issue.26, pp.2509-2529, 2015.

N. J. Llosa, M. Cruise, A. Tam, E. C. Wicks, E. M. Hechenbleikner et al., The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints, Cancer Discov. janv, vol.5, issue.1, pp.43-51, 2015.

M. Yarchoan, A. Hopkins, and E. M. Jaffee, Tumor Mutational Burden and Response Rate to PD-1 Inhibition

, N Engl J Med, vol.21, issue.25, pp.2500-2501, 2017.

A. M. Goodman, S. Kato, L. Bazhenova, S. P. Patel, G. M. Frampton et al., Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers, Mol Cancer Ther, vol.16, issue.11, pp.2598-608, 2017.

E. M. Van-allen, D. Miao, B. Schilling, S. A. Shukla, C. Blank et al., Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, vol.350, issue.6257, pp.207-218, 2015.

N. A. Rizvi, M. D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov et al., Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science. 3 avr, vol.348, issue.6230, pp.124-132, 2015.

W. Hugo, J. M. Zaretsky, L. Sun, C. Song, B. H. Moreno et al., Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma, Cell. 24 mars, vol.165, issue.1, pp.35-44, 2016.

M. D. Hellmann, T. Ciuleanu, A. Pluzanski, J. S. Lee, G. A. Otterson et al., Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden, N Engl J Med. 31 mai, vol.378, issue.22, pp.2093-104, 2018.

I. Buchhalter, E. Rempel, V. Endris, M. Allgäuer, O. Neumann et al., Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis, Int J Cancer, vol.15, issue.4, pp.848-58, 2019.

N. Vincent, O. Dassonville, E. Chamorey, G. Poissonnet, C. Pierre et al., Clinical and histological prognostic factors in locally advanced oral cavity cancers treated with primary surgery, Eur Ann Otorhinolaryngol Head Neck Dis. déc, vol.129, issue.6, pp.291-297, 2012.

C. Moore, M. B. Flynn, and R. A. Greenberg, Evaluation of size in prognosis of oral cancer, Cancer. 1 juill, vol.58, issue.1, pp.158-62, 1986.

P. Jehn, J. Dittmann, R. Zimmerer, R. Stier, M. Jehn et al., Survival Rates According to Tumour Location in Patients With Surgically Treated Oral and Oropharyngeal Squamous Cell Carcinoma, Anticancer Res. mai, vol.39, issue.5, pp.2527-2560, 2019.

B. Braakhuis, M. M. Rietbergen, M. Buijze, P. Snijders, E. Bloemena et al., TP53 mutation and human papilloma virus status of oral squamous cell carcinomas in young adult patients, Oral Dis. sept, vol.20, issue.6, pp.602-610, 2014.

X. Liang, J. Lewis, R. Foote, D. Smith, and D. Kademani, Prevalence and significance of human papillomavirus in oral tongue cancer: the Mayo Clinic experience, J Oral Maxillofac Surg. sept, vol.66, issue.9, pp.1875-80, 2008.

J. Brägelmann, I. Dagogo-jack, E. Dinali, M. Stricker, T. Brown et al., Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA, Oral Oncol. juin, vol.49, issue.6, pp.525-558, 2013.

J. S. Poling, X. Ma, S. Bui, Y. Luo, R. Li et al., Human papillomavirus (HPV) status of nontobacco related squamous cell carcinomas of the lateral tongue, Oral Oncol. avr, vol.50, issue.4, pp.306-316, 2014.

L. A. Ravasz, P. J. Slootweg, G. J. Hordijk, F. Smit, and I. Van-der-tweel, The status of the resection margin as a prognostic factor in the treatment of head and neck carcinoma, J Craniomaxillofac Surg. oct, vol.19, issue.7, pp.314-322, 1991.

L. A. Zieske, J. T. Johnson, E. N. Myers, P. B. Thearle, P. Garzino-demo et al., Squamous cell carcinoma with positive margins. Surgery and postoperative irradiation, Arch Otolaryngol Head Neck Surg. août, vol.112, issue.8, pp.863-869, 1986.

, Clinicopathological parameters and outcome of 245 patients operated for oral squamous cell carcinoma, J Craniomaxillofac Surg. sept, vol.34, issue.6, pp.344-50, 2006.

G. El-husseiny, A. Kandil, A. Jamshed, Y. Khafaga, M. Saleem et al., Squamous cell carcinoma of the oral tongue: an analysis of prognostic factors, Br J Oral Maxillofac Surg. juin, vol.38, issue.3, pp.193-202, 2000.

S. Kantola, M. Parikka, K. Jokinen, K. Hyrynkangs, Y. Soini et al., Prognostic factors in tongue cancer -relative importance of demographic, clinical and histopathological factors, Br J Cancer. sept, vol.83, issue.5, pp.614-623, 2000.

J. Hsu, W. Liu, S. Wong, Y. Poon, C. Jiang et al., Prognostic factors in patients with buccal squamous cell carcinoma: 10-year experience, J Oral Maxillofac Surg. févr, vol.69, issue.2, pp.396-404, 2011.

H. B. Jones, A. Sykes, N. Bayman, P. Sloan, R. Swindell et al., The impact of lymphovascular invasion on survival in oral carcinoma, Oral Oncol. janv, vol.45, issue.1, pp.10-15, 2009.

K. Sandu, L. Nisa, P. Monnier, C. Simon, S. Andrejevic-blant et al., Clinicobiological progression and prognosis of oral squamous cell carcinoma in relation to the tumor invasive front: impact on prognosis, Acta Otolaryngol. avr, vol.134, issue.4, pp.416-440, 2014.

J. G. Batsakis, Invasion of the microcirculation in head and neck cancer, Ann Otol Rhinol Laryngol. déc, vol.93, issue.6, pp.646-653, 1984.

G. Mamelle, J. Pampurik, B. Luboinski, R. Lancar, A. Lusinchi et al., Lymph node prognostic factors in head and neck squamous cell carcinomas, Am J Surg, vol.168, issue.5, pp.494-502, 1994.

R. L. Carter, J. M. Bliss, K. C. Soo, O. 'brien, and C. J. , Radical neck dissections for squamous carcinomas: pathological findings and their clinical implications with particular reference to transcapsular spread, Int J Radiat Oncol Biol Phys. juin, vol.13, issue.6, pp.825-857, 1987.

H. Hirabayashi, K. Koshii, K. Uno, H. Ohgaki, Y. Nakasone et al., Extracapsular spread of squamous cell carcinoma in neck lymph nodes: prognostic factor of laryngeal cancer, Laryngoscope. mai, vol.101, issue.5, pp.502-508, 1991.

T. A. Chan, M. Yarchoan, E. Jaffee, C. Swanton, S. A. Quezada et al., Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic, Ann Oncol. 1 janv, vol.30, issue.1, pp.44-56, 2019.

J. Kang, Y. Luo, D. Wang, Y. Men, J. Wang et al., Tumor Mutation Load: A Novel Independent Prognostic Factor in Stage IIIA-N2 Non-Small-Cell Lung Cancer, Dis Markers, p.3837687, 2019.

P. Jernvall, M. J. Mäkinen, T. J. Karttunen, J. Mäkelä, and P. Vihko, Microsatellite instability: impact on cancer progression in proximal and distal colorectal cancers, Eur J Cancer. févr, vol.35, issue.2, pp.197-201, 1999.

H. Kim, J. J. Vogelstein, B. Hamilton, and S. R. , Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences, Am J Pathol. juill, vol.145, issue.1, pp.148-56, 1994.

D. M. Graham and H. D. Appelman, Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator, Mod Pathol. mai, vol.3, issue.3, pp.332-337, 1990.

T. Eder, A. K. Hess, R. Konschak, C. Stromberger, K. Jöhrens et al., Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group, Eur J Cancer. juill, vol.116, pp.67-76, 2019.

P. A. Ott, Y. Bang, S. A. Piha-paul, A. Razak, J. Bennouna et al., T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028, J Clin Oncol. 1 févr, vol.37, issue.4, pp.318-345, 2019.

P. G. Coulie, B. J. Van-den-eynde, P. Van-der-bruggen, and T. Boon, Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy, Nat Rev Cancer. févr, vol.14, issue.2, pp.135-181, 2014.

B. M. Carreno, V. Magrini, M. Becker-hapak, S. Kaabinejadian, J. Hundal et al., Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells, Science. 15 mai, vol.348, issue.6236, pp.803-811, 2015.

L. B. Alexandrov, S. Nik-zainal, D. C. Wedge, S. Aparicio, S. Behjati et al., Signatures of mutational processes in human cancer, Nature. 22 août, vol.500, issue.7463, pp.415-436, 2013.

N. Mcgranahan, A. Furness, R. Rosenthal, S. Ramskov, R. Lyngaa et al., Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science. 25 mars, vol.351, issue.6280, pp.1463-1472, 2016.

G. Goh, T. Walradt, V. Markarov, A. Blom, N. Riaz et al., Mutational landscape of MCPyVpositive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy, Oncotarget. 19 janv, vol.7, issue.3, pp.3403-3418, 2016.